RU2010107199A - Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений - Google Patents
Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений Download PDFInfo
- Publication number
- RU2010107199A RU2010107199A RU2010107199/04A RU2010107199A RU2010107199A RU 2010107199 A RU2010107199 A RU 2010107199A RU 2010107199/04 A RU2010107199/04 A RU 2010107199/04A RU 2010107199 A RU2010107199 A RU 2010107199A RU 2010107199 A RU2010107199 A RU 2010107199A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- tumor
- pathogen
- antigenic determinant
- cell
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 5
- 230000001613 neoplastic effect Effects 0.000 title claims 5
- 238000009169 immunotherapy Methods 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002458 infectious effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract 55
- 102000036639 antigens Human genes 0.000 claims abstract 55
- 108091007433 antigens Proteins 0.000 claims abstract 55
- 206010028980 Neoplasm Diseases 0.000 claims abstract 36
- 230000000890 antigenic effect Effects 0.000 claims abstract 34
- 244000052769 pathogen Species 0.000 claims abstract 34
- 230000001717 pathogenic effect Effects 0.000 claims abstract 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 22
- 229920001184 polypeptide Polymers 0.000 claims abstract 21
- 108020001507 fusion proteins Proteins 0.000 claims abstract 12
- 102000037865 fusion proteins Human genes 0.000 claims abstract 12
- 230000008685 targeting Effects 0.000 claims abstract 12
- 210000004881 tumor cell Anatomy 0.000 claims abstract 12
- 239000013543 active substance Substances 0.000 claims abstract 10
- 229960005486 vaccine Drugs 0.000 claims abstract 8
- 244000005700 microbiome Species 0.000 claims abstract 6
- 210000005166 vasculature Anatomy 0.000 claims abstract 6
- 102000039446 nucleic acids Human genes 0.000 claims abstract 3
- 108020004707 nucleic acids Proteins 0.000 claims abstract 3
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims 9
- 210000002865 immune cell Anatomy 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 210000004479 myeloid suppressor cell Anatomy 0.000 claims 3
- 230000035515 penetration Effects 0.000 claims 3
- 210000003289 regulatory T cell Anatomy 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 claims 2
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- -1 small molecule tyrosine kinase inhibitor Chemical class 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 239000003292 glue Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
1. Композиция, содержащая: ! (а) нацеливающую часть, где указанная нацеливающая часть связывается с компонентом опухолевой клетки, микроокружения опухоли, сосудистой сети опухоли, опухолевым антигеном, связанным с опухолью антигеном, молекулой поверхности опухолевой клетки, опухолевой антигенной детерминантой или содержащим опухолевый антиген слитым белком; и ! (b) биологически активный агент, где указанный биологически активный агент содержит: ! i) полипептид антигена или антигенной детерминанты, где указанный полипептид антигена или антигенной детерминанты содержит компонент патогена, микроорганизма, антигена патогена, антигенной детерминанты патогена, связанного с патогеном антигена или содержащего антиген патогена слитого белка, ! и указанный полипептид антигена или антигенной детерминанты получен из вакцины; или ! ii) нуклеиновую кислоту, кодирующую полипептид антигена или антигенной детерминанты, ! где указанный полипептид антигена или антигенной детерминанты содержит компонент патогена, микроорганизма, антигена патогена, антигенной детерминанты патогена, связанного с патогеном антигена или содержащего антиген патогена слитого белка, ! и указанный полипептид антигена или антигенной детерминанты получен из вакцины. !2. Композиция, содержащая: !(а) нацеливающую часть, где указанная нацеливающая часть связывается с: ! i) компонентом опухолевой клетки, микроокружения опухоли, сосудистой сети опухоли, опухолевым антигеном, связанным с опухолью антигеном, молекулой поверхности опухолевой клетки, антигенной детерминантой опухоли или содержащим опухолевый антиген слитым белком; или ! ii) иммунной кле
Claims (9)
1. Композиция, содержащая:
(а) нацеливающую часть, где указанная нацеливающая часть связывается с компонентом опухолевой клетки, микроокружения опухоли, сосудистой сети опухоли, опухолевым антигеном, связанным с опухолью антигеном, молекулой поверхности опухолевой клетки, опухолевой антигенной детерминантой или содержащим опухолевый антиген слитым белком; и
(b) биологически активный агент, где указанный биологически активный агент содержит:
i) полипептид антигена или антигенной детерминанты, где указанный полипептид антигена или антигенной детерминанты содержит компонент патогена, микроорганизма, антигена патогена, антигенной детерминанты патогена, связанного с патогеном антигена или содержащего антиген патогена слитого белка,
и указанный полипептид антигена или антигенной детерминанты получен из вакцины; или
ii) нуклеиновую кислоту, кодирующую полипептид антигена или антигенной детерминанты,
где указанный полипептид антигена или антигенной детерминанты содержит компонент патогена, микроорганизма, антигена патогена, антигенной детерминанты патогена, связанного с патогеном антигена или содержащего антиген патогена слитого белка,
и указанный полипептид антигена или антигенной детерминанты получен из вакцины.
2. Композиция, содержащая:
(а) нацеливающую часть, где указанная нацеливающая часть связывается с:
i) компонентом опухолевой клетки, микроокружения опухоли, сосудистой сети опухоли, опухолевым антигеном, связанным с опухолью антигеном, молекулой поверхности опухолевой клетки, антигенной детерминантой опухоли или содержащим опухолевый антиген слитым белком; или
ii) иммунной клеткой;
(b) биологически активный агент, где указанный биологически активный агент содержит:
i) иммуностимуляторную молекулу, содержащую связанную с патогеном молекулярную структуру (PAMP), связанную с повреждением молекулярную структуру (DAMP)/алармин или их комбинацию,
ii) молекулу, которая истощает или инактивирует регуляторные Т-клетки, супрессорные Т-клетки или миелоидные супрессорные клетки или
iii) их комбинацию; и
(с) усиливающий проникновение в клетку пептид.
3. Композиция для индукции иммунной реакции, содержащая: один или несколько усиливающих проникновение в клетку пептидов, слитых или конъюгированных с одним или несколькими полипептидами антигенной детерминанты и одним или несколькими антигенами патогена.
4. Способ профилактики или лечения неопластического нарушения, включающий:
введение пациенту терапевтически эффективного количества композиции, содержащей:
(а) нацеливающую часть, где указанная нацеливающая часть связывается с компонентом опухолевой клетки, микроокружения опухоли, сосудистой сети опухоли, опухолевым антигеном, связанным с опухолью антигеном, молекулой поверхности опухолевой клетки, опухолевой антигенной детерминантой или содержащим опухолевый антиген слитым белком; и
(b) биологически активный агент, где указанный биологически активный агент содержит:
i) полипептид антигена или антигенной детерминанты, где указанный полипептид антигена или антигенной детерминанты содержит компонент патогена, микроорганизма, антигена патогена, антигенной детерминанты патогена, антигена, связанного с патогеном или содержащего антиген патогена слитого белка,
и указанный полипептид антигена или антигенной детерминанты получен из вакцины; или
ii) нуклеиновую кислоту, кодирующую полипептид антигена или антигенной детерминанты,
где указанный полипептид антигена или антигенной детерминанты содержит компонент патогена, микроорганизма, антигена патогена, антигенной детерминанты патогена, антигена, связанного с патогеном или содержащего антиген патогена слитого белка,
и указанный полипептид антигена или антигенной детерминанты получен из вакцины.
5. Способ лечения неопластического нарушения, включающий:
введение пациенту терапевтически эффективного количества композиции, содержащей:
(а) полипептид антигенной детерминанты, где указанный полипептид антигенной детерминанты
i. содержит антигенную детерминанту из вакцины патогена, где указанная вакцина получена из столбняка, дифтерии, коклюша, пневмококка, вируса гриппа, вируса гепатита или их комбинации, или
ii. конъюгирован или слит с усиливающим проникновение в клетку пептидом; и
(b) противораковый терапевтический агент, где указанный противораковый агент содержит:
i. химиотерапевтический агент, антитело, ингибитор тирозинкиназы с малой молекулой, цитокин, нацеленный терапевтический агент, гормональный терапевтический агент, антиангиогенный агент, облучение, термическое удаление, криоудаление, высокочастотное удаление, электропорацию, фокусируемый ультразвук высокой интенсивности;
ii. молекулу, которая истощает или инактивирует регуляторные Т-клетки, супрессорные Т-клетки или миелоидные супрессорные клетки, или
iii. их комбинацию.
6. Способ ex vivo активации иммунных клеток, включающий контактирование иммунной клетки с композицией по п.1 или 2.
7. Способ профилактики или лечения неопластического нарушения, включающий:
введение пациенту терапевтически эффективного количества композиции, содержащей:
(а) нацеливающую часть, где указанная нацеливающая часть связывается с
(i) компонентом опухолевой клетки, микроокружения опухоли, сосудистой сети опухоли, опухолевым антигеном, связанным с опухолью антигеном, молекулой поверхности опухолевой клетки, опухолевой антигенной детерминантой или содержащим опухолевый антиген слитым белком; или
(ii) иммунной клеткой;
(b) биологически активный агент, где указанный биологически активный агент содержит:
i) иммуностимуляторную молекулу, содержащую связанную с патогеном молекулярную структуру (PAMP), связанную с повреждением молекулярную структуру (DAMP)/алармин или их комбинацию,
ii) молекулу, которая истощает или инактивирует регуляторные Т-клетки, супрессорные Т-клетки или миелоидные супрессорные клетки, или
(iii) их комбинацию; и
(с) усиливающий проникновение в клетку пептид.
8. Способ получения композиции, содержащей иммунную клетку, где указанный способ получения включает указанный способ по п.4, 5 или 7.
9. Способ лечения пациента с неопластическим нарушением, включающий введение пациенту терапевтически эффективного количества композиции, содержащей иммунную клетку, полученной указанным способом по п.8.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US789507P | 2007-07-31 | 2007-07-31 | |
US61/007,895 | 2007-07-31 | ||
US2217308P | 2008-01-18 | 2008-01-18 | |
US61/022,173 | 2008-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2010107199A true RU2010107199A (ru) | 2011-09-10 |
Family
ID=40304902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010107199/04A RU2010107199A (ru) | 2007-07-31 | 2008-07-31 | Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090123467A1 (ru) |
EP (1) | EP2178896A1 (ru) |
JP (1) | JP2010535248A (ru) |
KR (1) | KR20100063048A (ru) |
CN (1) | CN102317303A (ru) |
AU (1) | AU2008283802A1 (ru) |
CA (1) | CA2695385A1 (ru) |
GB (1) | GB2464887A (ru) |
MX (1) | MX2010001194A (ru) |
RU (1) | RU2010107199A (ru) |
TR (1) | TR201000668T1 (ru) |
WO (1) | WO2009018500A1 (ru) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5285278B2 (ja) | 2004-12-22 | 2013-09-11 | クリーブランド クリニック ファウンデイション | フラゲリン関連ポリペプチドおよびその使用 |
ES2804472T3 (es) | 2005-12-13 | 2021-02-08 | Harvard College | Estructuras para trasplante celular |
EP2056845B1 (en) | 2006-08-08 | 2017-10-11 | Rheinische Friedrich-Wilhelms-Universität Bonn | Structure and use of 5' phosphate oligonucleotides |
WO2009002401A2 (en) | 2007-06-21 | 2008-12-31 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
EP2254602B1 (en) | 2008-02-13 | 2018-11-21 | President and Fellows of Harvard College | Continuous cell programming devices |
CN102014937A (zh) | 2008-03-03 | 2011-04-13 | 迈阿密大学 | 基于异基因癌细胞的免疫治疗 |
EP2300022A2 (en) | 2008-04-25 | 2011-03-30 | Duke University | Regulatory b cells and their uses |
JP5689413B2 (ja) | 2008-05-21 | 2015-03-25 | ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン | 平滑末端を有する5’三リン酸オリゴヌクレオチドおよびその使用 |
EA020579B1 (ru) | 2008-08-01 | 2014-12-30 | Кливленд Байолэбс, Инк. | Способ лечения реперфузионных повреждений тканей |
US9192649B2 (en) * | 2008-10-17 | 2015-11-24 | London Health Sciences Centre Research Inc. | Annexin and its use to treat inflammatory disorders |
EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
CA2753294A1 (en) | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Inc. | Proproteins and methods of use thereof |
EP2413964B1 (en) * | 2009-04-01 | 2019-11-13 | University of Miami | Vaccine compositions and methods of use thereof |
US20130209514A1 (en) * | 2009-06-09 | 2013-08-15 | Eli Gilboa | Aptamer-targeted costimulatory ligand aptamer |
US8728456B2 (en) * | 2009-07-31 | 2014-05-20 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
AU2010306645B2 (en) * | 2009-10-16 | 2017-03-23 | Baylor College Of Medicine | Supercoiled minicircle DNA for gene therapy applications |
AU2011215799A1 (en) * | 2010-02-12 | 2012-09-06 | Solulink, Inc. | Preparation and/or purification of oligonucleotide conjugates |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
EP2540311A4 (en) * | 2010-02-26 | 2016-07-06 | Univ Nagasaki | COMPOSITE BODY FOR RELEASING ANTIGENS OR MEDICAMENTS |
US9382366B2 (en) * | 2010-06-25 | 2016-07-05 | University Of Massachusetts | Protein transduction domains mimics |
US10131875B2 (en) | 2010-08-04 | 2018-11-20 | Duke University | Regulatory B cells and their uses |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US11202759B2 (en) | 2010-10-06 | 2021-12-21 | President And Fellows Of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
DK2638163T3 (en) | 2010-11-12 | 2017-07-24 | Massachusetts Gen Hospital | POLYCOMB-ASSOCIATED NON-CODING RNAs |
WO2012079115A1 (en) * | 2010-12-14 | 2012-06-21 | Commonwealth Scientific And Industrial Research Organisation | Immunostimulatory oligonucleotides |
US9814740B2 (en) | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
EP2471926A3 (en) * | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
AU2012205681B2 (en) * | 2011-01-10 | 2016-07-28 | Cleveland Biolabs, Inc. | Use of toll-like receptor agonist for treating cancer |
EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
US20140010886A1 (en) * | 2011-04-07 | 2014-01-09 | Georgia Tech Research Corporation | Compositions comprising saccharide binding moieties and methods for targeted therapy |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
EP2701745B1 (en) | 2011-04-28 | 2018-07-11 | President and Fellows of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
JP5872685B2 (ja) * | 2011-05-26 | 2016-03-01 | インターベット インターナショナル ベー. フェー. | 免疫刺激性オリゴデオキシヌクレオチド |
RU2587633C2 (ru) * | 2011-05-26 | 2016-06-20 | Интервет Интернэшнл Б.В. | Иммуностимулирующие олигодезоксинуклеотиды |
JP6062426B2 (ja) | 2011-06-03 | 2017-01-18 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | インサイチュー抗原生成癌ワクチン |
BR112013032675A2 (pt) * | 2011-06-19 | 2017-08-08 | Vaxine Pty Ltd | composição adjuvante de vacina compreendendo partículas de inulina |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
ES2773895T3 (es) | 2012-04-16 | 2020-07-15 | Harvard College | Composiciones de sílice mesoporosa para modular las respuestas inmunitarias |
AU2013262663A1 (en) | 2012-05-16 | 2015-01-22 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Compositions and methods for modulating gene expression |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
AU2013262709A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
KR102499944B1 (ko) | 2012-11-15 | 2023-02-14 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
CN103396996B (zh) * | 2013-01-30 | 2014-12-31 | 无锡贝瑞康生物科技有限公司 | 一种携带TGF-βRⅡ和NKG2D基因的NK92细胞株、制备方法及用途 |
KR20150003617A (ko) * | 2013-07-01 | 2015-01-09 | 서강대학교산학협력단 | 바이오 프로세싱 장치 |
US20150050313A1 (en) * | 2013-08-16 | 2015-02-19 | The Regents Of The University Of California | Novel immunostimulants and synthesis thereof |
MX369469B (es) | 2013-08-21 | 2019-11-08 | Curevac Ag | Vacuna contra el virus respiratorio sincitial. |
CN105658230B (zh) * | 2013-08-29 | 2020-04-21 | 希望之城 | 细胞穿透缀合物及其使用方法 |
EP4374924A2 (en) | 2013-10-18 | 2024-05-29 | Novartis AG | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US10605810B2 (en) * | 2013-12-30 | 2020-03-31 | University-Industry Cooperation Group Of Kyung Hee University | Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof |
US10548985B2 (en) | 2014-01-10 | 2020-02-04 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for treating EGFR expressing tumors |
EP3909603A1 (en) | 2014-02-21 | 2021-11-17 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
AU2015240727A1 (en) * | 2014-04-03 | 2016-11-10 | Augusta University Research Institute, Inc. | Methods for enhancing the efficacy of a tumor-directed immune response |
JP7348708B2 (ja) | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 組み合わせワクチン装置および癌細胞を殺滅する方法 |
EP3166976B1 (en) | 2014-07-09 | 2022-02-23 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1 combinations for treating tumors |
KR20170031251A (ko) | 2014-07-30 | 2017-03-20 | 클리브랜드 바이오랩스, 아이엔씨. | 플라젤린 조성물 및 용도 |
CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于***的抗-pd-l1结合物 |
US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
WO2016070060A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
WO2016074580A1 (zh) * | 2014-11-14 | 2016-05-19 | 中国科学院上海生命科学研究院 | 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用 |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
IL284985B2 (en) | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
WO2016146143A1 (en) * | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
WO2016149455A2 (en) | 2015-03-17 | 2016-09-22 | The General Hospital Corporation | The rna interactome of polycomb repressive complex 1 (prc1) |
JP7094533B2 (ja) | 2015-04-10 | 2022-07-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫細胞捕捉デバイスおよびその製造および使用方法 |
KR20170138534A (ko) | 2015-04-21 | 2017-12-15 | 엔리벡스 테라퓨틱스 리미티드 | 치료적 혼주된 혈액 아폽토시스 세포 제제 및 이의 용도 |
US20180221508A1 (en) * | 2015-07-31 | 2018-08-09 | Tarveda Therapeutics, Inc. | Compositions and methods for immunomodulation |
CA3002674A1 (en) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
CN115554406A (zh) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | 用于***的抗-cd20组合 |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于***的抗-egfr组合 |
CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于***的抗-her2组合 |
CN115531609A (zh) | 2016-02-06 | 2022-12-30 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
EP3416661A4 (en) | 2016-02-18 | 2020-03-04 | Enlivex Therapeutics Ltd. | COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER |
US20210213138A1 (en) * | 2016-02-19 | 2021-07-15 | Genisphere Llc | Nucleic Acid Carriers And Therapeutic Methods of Use |
KR101859683B1 (ko) * | 2016-03-17 | 2018-07-02 | 서강대학교산학협력단 | 줄기세포 분화 제어를 위한 바이오몰레트론 |
EP3235515A1 (en) * | 2016-04-21 | 2017-10-25 | Eberhard Karls Universität Tübingen | Targeted mrna for in vivo application |
CN107441501B (zh) * | 2016-07-01 | 2020-11-10 | 四川大学 | 抗菌肽修饰的载药脂质体及其制备方法和用途 |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
AU2017295704B2 (en) | 2016-07-13 | 2023-07-13 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
JP7096249B2 (ja) * | 2016-09-04 | 2022-07-05 | ターグイミューン セラピューティクス アーゲー | dsRNAを標的化するためのキメラタンパク質 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
CN110248668B (zh) | 2016-12-15 | 2023-05-30 | 杜克大学 | 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用 |
CA3049791A1 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
WO2018144955A1 (en) * | 2017-02-02 | 2018-08-09 | Silverback Therapeutics, Inc. | Construct-peptide compositions and methods of use thereof |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
US11517567B2 (en) | 2017-06-23 | 2022-12-06 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
WO2019010471A1 (en) * | 2017-07-07 | 2019-01-10 | Wang tian xin | METHODS AND REAGENTS FOR TREATING AUTOIMMUNE DISEASES AND ALLERGY |
CN109453187B (zh) * | 2018-09-27 | 2020-12-29 | 天津医科大学 | 具有双重酶敏感特性的抗体核酸药物偶联物及其制备方法和应用 |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
CN110129328B (zh) * | 2019-04-25 | 2021-02-09 | 华中农业大学 | ltk基因在制备日本青鳉无背景荧光透明品系中的应用 |
CN110115764B (zh) * | 2019-05-07 | 2021-10-29 | 天津大学 | 一种声控肿瘤高效协同免疫治疗可视化微纳载体***及其制备方法、应用 |
CN110124055B (zh) * | 2019-05-14 | 2022-07-08 | 南京大学 | 一种靶向pd-l1的抗体-核酸偶联药物及其制备方法和应用 |
AU2020286523A1 (en) * | 2019-06-03 | 2022-02-03 | The University Of Chicago | Methods and compositions for treating cancer with cancer-targeted adjuvants |
CN110609020B (zh) * | 2019-08-15 | 2021-10-01 | 济南大学 | 基于回文分子信标检测atp的生物传感器及其制备方法和应用 |
EP4048689A4 (en) * | 2019-10-23 | 2023-11-01 | Cue Biopharma, Inc. | T-CELL MODULATING CHIMERIC MOLECULES AND METHOD OF USE THEREOF |
EP4058486A4 (en) * | 2019-11-12 | 2023-08-16 | Iprogen Biotech Inc. | ANTIBODY-PAYLOAD CONJUGATES WITH ENHANCED DELIVERY RANGE AND THEIR USES |
EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
CN113376146A (zh) * | 2020-02-25 | 2021-09-10 | 上海交通大学 | 适于生物分子多重检测的检测颗粒及其制备方法与应用 |
CA3183993A1 (en) | 2020-07-01 | 2022-01-06 | Peter R. Baum | Anti-asgr1 antibody conjugates and uses thereof |
CN113018432B (zh) * | 2021-03-11 | 2022-12-13 | 湖南大学 | 一种免疫药物的制备方法 |
KR20230165829A (ko) * | 2021-04-02 | 2023-12-05 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 이중특이적 분자 및 관련 조성물 및 방법 |
CN114028545A (zh) * | 2021-11-30 | 2022-02-11 | 中国科学院昆明动物研究所 | 一种抗病毒感染ll-37-dna复合物及其应用 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4244946A (en) * | 1979-06-11 | 1981-01-13 | The Salk Institute For Biological Studies | Water-soluble peptides affecting gonadal function |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US7273695B1 (en) * | 1984-10-31 | 2007-09-25 | Novartis Vaccines And Diagnostics, Inc. | HIV immunoassays using synthetic envelope polypeptides |
US6905680B2 (en) * | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5378805A (en) * | 1990-08-29 | 1995-01-03 | United States Of America | Immunoreactive HTLV-I/II ENV and POL peptides |
US7060283B1 (en) * | 1992-09-15 | 2006-06-13 | Ortho Diagnostic Systems, Inc. | Immunoreactive peptides from Epstein-Barr virus |
WO1994027150A1 (en) * | 1993-05-10 | 1994-11-24 | Nissui Pharmaceutical Co., Ltd. | Method for assaying more than one immunological ligand, and assay reagent and kit therefor |
US5596081A (en) * | 1994-03-11 | 1997-01-21 | University Of Kentucky Research Foundation | Nucleotide or nucleoside photoaffinity compound modified antibodies, methods for their manufacture and use thereof as diagnostics and therapeutics |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US7038026B2 (en) * | 2000-05-26 | 2006-05-02 | Centelion | Purification of a triple heli formation with an immobilized oligonucleotide |
FR2731014B1 (fr) * | 1995-02-23 | 1997-03-28 | Rhone Poulenc Rorer Sa | Molecules d'adn, preparation et utilisation en therapie genique |
DE69733944T3 (de) * | 1996-02-21 | 2012-07-26 | The Board Of Regents, The University Of Texas System | Vmp-ähnliche sequenzen von pathogener borrelia |
ATE292980T1 (de) * | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
GB9711115D0 (en) * | 1997-05-29 | 1997-07-23 | Inst Of Child Health | Integrin-targeting vectors having enhanced transfection activity |
CA2291483C (en) * | 1997-06-06 | 2012-09-18 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US6589940B1 (en) * | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
FR2766495B1 (fr) * | 1997-07-22 | 2001-07-13 | Pasteur Institut | Souche de mycobacterium dont le gene erp est modifie et composition vaccinale la contenant |
EP1053355B1 (en) * | 1998-02-11 | 2001-11-14 | PE Corporation (NY) | Pna and dna conjugates and methods for preparation thereof |
ES2284247T3 (es) * | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
MXPA02003108A (es) * | 1999-09-25 | 2003-10-14 | Univ Iowa Res Found | Acidos nucleicos inmunoestimuladores. |
JP2004509970A (ja) * | 2000-09-26 | 2004-04-02 | ハイブリドン・インコーポレイテッド | 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節 |
GB0025307D0 (en) * | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
US20030175287A1 (en) * | 2001-01-03 | 2003-09-18 | Yale University | Innate immune system-directed vaccines |
CN1309417C (zh) * | 2001-02-15 | 2007-04-11 | 王荣福 | 穿细胞肽在产生抗肿瘤免疫力上的用途 |
US20040109869A1 (en) * | 2001-03-19 | 2004-06-10 | Iomai Corporation | Transcutaneous immunostimulation |
EP1425039A4 (en) * | 2001-03-23 | 2005-02-02 | Us Gov Health & Human Serv | PEPTIDES THAT GIVE AN IMMUNE REACTION WITH THE HUMAN PAPILLOMA VIRUS |
US20050129616A1 (en) * | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
EP1288244A1 (en) * | 2001-08-31 | 2003-03-05 | Asahi Glass Company, Limited | Double metal cyanide complex catalyst for ring opening polymerization of alkylene oxide and its production process |
WO2003094836A2 (en) * | 2001-10-12 | 2003-11-20 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US6942972B2 (en) * | 2001-10-24 | 2005-09-13 | Beckman Coulter, Inc. | Efficient synthesis of protein-oligonucleotide conjugates |
US20070003514A1 (en) * | 2002-04-05 | 2007-01-04 | The Regents Of The University Of California | Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination |
AU2003221650A1 (en) * | 2002-04-24 | 2003-11-10 | Universite Libre De Bruxelles | Mutated hpv-16 e7 polypeptide, pharmaceutical composition comprising it and its preparation process |
WO2003091418A2 (en) * | 2002-04-26 | 2003-11-06 | Bristol-Myers Squibb Company | Novel essential fungal polynucleotides, polypeptides, and methods of use |
US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
DE60332277D1 (de) * | 2002-11-26 | 2010-06-02 | Univ Massachusetts | Verabreichung von sirnas |
MXPA05008222A (es) * | 2003-01-31 | 2005-10-05 | Immunomedics Inc | Metodos y composiciones para administrar agentes terapeuticos y de diagnostico. |
EP1641927B1 (en) * | 2003-02-18 | 2015-07-08 | Baylor College of Medicine | Induced activation in dendritic cells |
AT412400B (de) * | 2003-05-08 | 2005-02-25 | Mayrhofer Peter Mag Dr | Minicircle-herstellung |
WO2005018539A2 (en) * | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
AU2005230848B9 (en) * | 2004-03-31 | 2011-06-02 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
JP2008508860A (ja) * | 2004-06-03 | 2008-03-27 | メダレツクス・インコーポレーテツド | Fcγ受容体1(CD64)に対するヒトモノクローナル抗体 |
US20080051323A1 (en) * | 2004-08-21 | 2008-02-28 | Kosak Kenneth M | Chloroquine drug compositions and methods for their synthesis |
US7196768B2 (en) * | 2004-10-26 | 2007-03-27 | Asml Netherlands B.V. | Lithographic apparatus and device manufacturing method |
CA2586913A1 (en) * | 2004-11-09 | 2006-05-18 | University Of Southern California | Targeted innate immunity |
WO2006078979A2 (en) * | 2005-01-20 | 2006-07-27 | Nature Technology Corp. | Vectors and methods for genetic immunization |
US7604935B2 (en) * | 2005-10-26 | 2009-10-20 | Roche Diagnostics Operations, Inc. | Soluble rubella E1 envelope protein variants |
EP1790358A1 (en) * | 2005-11-23 | 2007-05-30 | Université de Reims Champagne-Ardennes | Protein constructs designed for targeting and lysis of cells |
EP1986698A2 (en) * | 2006-02-01 | 2008-11-05 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
US20080031887A1 (en) * | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
-
2008
- 2008-07-31 EP EP08797017A patent/EP2178896A1/en not_active Withdrawn
- 2008-07-31 CA CA2695385A patent/CA2695385A1/en not_active Abandoned
- 2008-07-31 JP JP2010520207A patent/JP2010535248A/ja active Pending
- 2008-07-31 WO PCT/US2008/071858 patent/WO2009018500A1/en active Application Filing
- 2008-07-31 RU RU2010107199/04A patent/RU2010107199A/ru not_active Application Discontinuation
- 2008-07-31 GB GB1003411A patent/GB2464887A/en not_active Withdrawn
- 2008-07-31 KR KR1020107004280A patent/KR20100063048A/ko not_active Application Discontinuation
- 2008-07-31 CN CN2008801097416A patent/CN102317303A/zh active Pending
- 2008-07-31 TR TR2010/00668T patent/TR201000668T1/xx unknown
- 2008-07-31 AU AU2008283802A patent/AU2008283802A1/en not_active Abandoned
- 2008-07-31 US US12/184,246 patent/US20090123467A1/en not_active Abandoned
- 2008-07-31 MX MX2010001194A patent/MX2010001194A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2008283802A1 (en) | 2009-02-05 |
JP2010535248A (ja) | 2010-11-18 |
TR201000668T1 (tr) | 2010-06-21 |
GB2464887A (en) | 2010-05-05 |
CN102317303A (zh) | 2012-01-11 |
WO2009018500A8 (en) | 2010-03-11 |
EP2178896A1 (en) | 2010-04-28 |
WO2009018500A1 (en) | 2009-02-05 |
CA2695385A1 (en) | 2009-02-05 |
GB201003411D0 (en) | 2010-04-14 |
MX2010001194A (es) | 2010-07-30 |
US20090123467A1 (en) | 2009-05-14 |
KR20100063048A (ko) | 2010-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010107199A (ru) | Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений | |
Brown et al. | RNA bacteriophage capsid-mediated drug delivery and epitope presentation | |
KR101650364B1 (ko) | 항원-특이적인 t 세포 반응을 유도하는 면역 강화제로서 사용을 위한 융합 단백질 | |
Pastori et al. | Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41 | |
JP2003505431A5 (ru) | ||
JP2013528229A5 (ru) | ||
US11078491B2 (en) | Vaccines against Zika virus based on Zika structure proteins | |
CN108770357A (zh) | 聚合物结合疫苗 | |
RU2011121043A (ru) | ВАКЦИНА ПРОТИВ ПЕПТИДА CH3 IgE | |
US20080031849A1 (en) | Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors | |
McGaughey et al. | Progress towards the development of a HIV-1 gp41-directed vaccine | |
Xu et al. | A DNA-launched nanoparticle vaccine elicits CD8+ T-cell immunity to promote in vivo tumor control | |
CN113396155A (zh) | 偶联病毒样颗粒及其作为抗肿瘤免疫重定向剂的用途 | |
Zhou et al. | RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern | |
Brumeanu et al. | Immunogenicity of a contiguous TB synthetic epitope of the A/PR/8/34 influenza virus | |
Demircan et al. | Biotin functionalized self‐assembled peptide nanofiber as an adjuvant for immunomodulatory response | |
Narayanan et al. | Recombinant helical plant virus-based nanoparticles for vaccination and immunotherapy | |
Svanholm et al. | Amplification of T‐cell and antibody responses in DNA‐based immunization with HIV‐1 Nef by co‐injection with a GM‐CSF expression vector | |
RU2007112117A (ru) | Вакцинная композиция против вируса гепатита с | |
WO2021248017A2 (en) | Chimeric adenoviral vectors | |
WO2023236726A1 (zh) | 基于金属硫蛋白家族的免疫佐剂及其应用 | |
US10660949B2 (en) | Vaccination using plant virus particles linked to HER2 antigens | |
CA3121843A1 (en) | Virus-like particles of cmv modified by fusion | |
Khawaja et al. | Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation | |
HRP930658A2 (en) | Improved vaccine compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20131101 |